Clinical trials: Hepatitis C Virus
Chronic Hepatitis C Virus Genotype 1
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I
Based on 12-week on-treatment data, at least 1 dose of BMS-824393 can be identified which is safe, well tolerated, and has sufficient antiviral activity to progress to late stage clinical trials when combined with pegIFNα/RBV for…
- Trial name
- NCT01142700
- Testing
- BMS-824393, Peginterferon Alpha-2a, Ribavirin
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C
This randomized, cross-over, open label study will compare the tolerability and handling of application of peginterferon alfa-2a [Pegasys] by autoinjector versus pre-filled syringe in patients with chronic hepatitis C, either on…
- Trial name
- NCT01087944
- Testing
- Autoinjector, Pre-filled syringe
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive…
- Trial name
- NCT01851330
- Testing
- LDV/SOF, RBV
- Where
- 52 sites in United States
- Volunteers
- 647 people
- Sponsor
- Gilead Sciences
Hepatitis C
VX-950 and Peginterferon for Hepatitis C
VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.
- Trial name
- NCT00251199
- Testing
- VX-950, peginterferon
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis C
VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram
The purpose of this study is to investigate the effect of steady-state telaprevir (TVR) 750 mg q8h (3 times a day, every 8 hours) on the steady-state pharmacokinetics of escitalopram 10 mg q.d. (once a day), and vice versa.
- Trial name
- NCT00933894
- Testing
- Telaprevir; Escitalopram
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
HEPATITIS C (HCV)
Lay User Evaluation of the Panbio™ HCV Self-Test
This is a prospective, multi-centre study designed to evaluate the usability of the Panbio™ HCV Self Test, when performed by untrained lay users in an observed study setting.
- Trial name
- NCT06605573
- Testing
- Panbio™ HCV Self Test
- Volunteers
- 1,185 people, healthy volunteers welcome
- Sponsor
- Abbott Rapid Dx
Hepatitis C Virus Infection
Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection
This post-marketing surveillance (PMS) study for Sovaldi® tablets (sofosbuvir, SOF) administered in combination with Copegus® tablets (ribavirin, COPE) will evaluate the safety and efficacy of SOF administered in combination with…
- Trial name
- NCT02537379
- Testing
- SOF, COPE
- Where
- 45 sites in Japan
- Volunteers
- 552 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic, Hepacivirus
Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)
Patients receiving a patient assistance program during therapy for Hepatitis C will be enrolled into this study. All patients will receive PegIntron and Rebetol (according to the label) and the patient assistance program, which…
- Trial name
- NCT00723879
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908), Patient assistance program
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population
Hepatitis C is a global problem, prevalent in developed as well as in the developing countries. New treatment regimens using PegInterferon in combination with ribavirin has led to improved sustained viral response rates for some…
- Trial name
- EUROP (NCT02601976)
- Testing
- Peginterferon alfa-2a, Ribavirin
- Volunteers
- 64 people
- Sponsor
- Getz Pharma
HCV Infection
Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)
The purpose of this study is to assess the pharmacokinetics (PK), safety, and efficacy of oral MK-5172 (a fixed dose combination [FDC] tablet containing elbasvir [EBR] 50 mg and grazoprevir [GZR] 100 mg) and EBR/GZR (varying…
- Trial name
- NCT03379506
- Testing
- EBR/GZR FDC Tablet, Grazoprevir Oral Granules, Elbasvir Oral Granules
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 57 people
- Sponsor
- Merck Sharp & Dohme LLC
Encephalitis
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease.
- Trial name
- NCT00381433
- Testing
- AVI-4065 Injection
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Hepatitis C, Chronic
KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C
This study aimed to confirm efficacy and safety of KW-136, an investigational anti-hepatitis C virus (HCV) drug, combined with sofosbuvir for treatment of naive and experienced adults chronically infected with HCV.
- Trial name
- KW-136_III (NCT03995485)
- Testing
- KW-136 capsule, Sofosbuvir
- Where
- 19 sites in China
- Volunteers
- 371 people
- Sponsor
- Kawin Technology Share-holding Co., Ltd.
Hepatitis C, Chronic
Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients
The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients.
- Trial name
- NCT02176525
- Testing
- BI 207127 NA
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and…
- Trial name
- NCT00077649
- Testing
- ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection
This randomized, open-label, active-controlled, parallel-group study will evaluate the sustained virological response of danoprevir boosted with low dose ritonavir in combination with Pegasys (peginterferon alfa-2a) and Copegus…
- Trial name
- NCT01220947
- Testing
- Copegus, Danoprevir, Pegasys
- Where
- 68 sites in United States, Austria and 9 more
- Volunteers
- 421 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance
Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the effect of filibuvir on the…
- Trial name
- NCT01210404
- Testing
- filibuvir
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Chronic Hepatitis C (HCV)
Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects
This is a proof-of-concept study which will provide data about the safety and antiviral activity of several doses of the investigational drug IDX184 given for 3 days in treatment-naive HCV genotype 1-infected subjects so that…
- Trial name
- NCT00807001
- Testing
- IDX184
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients
PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that is being developed as a potential treatment for hepatitis C virus infection.
- Trial name
- NCT01928147
- Testing
- PPI-383
- Where
- 6 sites in Mauritius, United Kingdom
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Presidio Pharmaceuticals, Inc.
Chronic Hepatitis C
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects
- Trial name
- HEC110114 (NCT04202952)
- Testing
- HEC110114 Tablet, Sofosbuvir Tablet
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.